Vertex Pharmaceuticals Incorporated (VRTX)

Environment story

The provided 10-K and proxy statement contain no disclosure of Scope 1, Scope 2, or Scope 3 greenhouse gas emissions, no stated net-zero target year, and no renewable-electricity percentage. Under the deterministic rubric, undisclosed Scope 3 data and an undisclosed net-zero target each trigger a 15-point deduction. No verified physical decarbonization infrastructure investments or carbon-offset programs are referenced in these filings, so no addition or greenwashing deduction is applied for offsets. A general operational risk factor citing hazardous-materials use and flood-zone-located facilities is noted but does not constitute a documented controversy with quantified severity, so no further deduction was applied for that item. This is a research data assessment, not investment advice.

Social story

Board-level gender diversity stands at approximately 45% (5 of 11 director nominees), above the 30% threshold, so no deduction applies for leadership diversity. No documented union-suppression activity, strikes, or NLRB complaints appear in the provided filings, so no deduction applies there. CEO-to-median-worker pay ratio is referenced by section title ('Pay Ratio') in the proxy but the specific ratio was not included in the provided excerpt, so no ratio-based deduction was applied absent verified data. No supply-chain human-rights audit findings (e.g., conflict minerals, forced labor) were disclosed in the provided text. A notable product-safety item is the FDA-mandated December 2024 boxed-warning label change for TRIKAFTA and ALYFTREK regarding liver injury/failure risk, which is presented here as a factual disclosure rather than a scored deduction under the defined rubric categories. This is a research data assessment, not investment advice.

Governance story

Board independence is 9 of 11 nominees (~82%), above the 75% threshold, so no deduction applies there. No dual-class share structure is disclosed; Vertex maintains a single class of common stock, though Massachusetts anti-takeover statutes and by-law provisions (staggered adjournment powers, blank-check preferred stock authority, business-combination restrictions on 20%+ holders) constrain shareholder influence. A modest deduction was applied for lobbying activity connected to opposing drug-pricing reform measures (e.g., IRA implementation, state Prescription Drug Affordability Boards, most-favored-nation pricing proposals), which the rubric treats as activity potentially weakening consumer-protection-oriented cost-containment policy. An additional modest deduction reflects generic disclosure of ongoing government investigations, subpoenas, and litigation common to the industry, plus an active arbitration over ALYFTREK royalty rights, though no specific antitrust, consumer-fraud, or SEC consent decree was confirmed in the provided filings. This is a research data assessment, not investment advice.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Vertex Pharmaceuticals Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Vertex Pharmaceuticals Incorporated in the app for interactive charts and portfolio building.

More in Healthcare